Aim Anaemia is common in heart failure and associated with worse outcomes. We examined the effect of dapagliflozin on correction anaemia patients (HF) reduced ejection fraction DAPA-HF. also analysed outcomes, according to status at baseline. Methods results was defined baseline as a haematocrit <39% men <36% women. Resolution two consecutive measurements above these thresholds any time during ...

ABSTRACT Background Per the guidelines established by European Society of Cardiology (ESC) for diagnosing and managing chronic acute heart failure, Sacubitril/Valsartan, Empagliflozin, Dapagliflozin are suggested to replace an angiotensin-converting enzyme (ACE) inhibitor significantly minimize failure (HF) associated risks including hospitalization possible death HF ambulatory patients with re...

OBJECTIVE The sodium-glucose transporter 2 (SGLT2) inhibitors Canagliflozin and Dapagliflozin are recently approved medications for type 2 diabetes. Recent studies indicate that SGLT2 inhibitors may inhibit the growth of some cancer cells but the mechanism(s) remain unclear. METHODS Cellular proliferation and clonogenic survival were used to assess the sensitivity of prostate and lung cancer ...

BACKGROUND Sodium glucose co-transporter 2 (SGLT2) inhibitors are a new class of pharmacologic agents developed for the treatment of type 2 diabetes mellitus (T2DM). Their unique mechanism of action is independent of pancreatic beta-cell function or the degree of insulin resistance, giving these agents the potential for use in combination with any of the existing classes of glucose-lowering age...

Heart Failure (HF) is a high-cost chronic disease with frequent worsening events requiring expensive hospital treatments. This study evaluated the cost-utility of dapagliflozin in patients HF Panama. A Markov model was developed considering three states: HF, and death. The base case an ejection fraction 40% or less New York Association class II, III, IV symptoms. Perspective from third payer; c...

Background: Heart failure (HF) is a major cause of recurrent hospitalization and death worldwide. Sodium-glucose cotransporter-2 inhibitors including Dapagliflozin are anti-diabetic drugs with promising cardiovascular (CV) effects. We performed systematic review meta-analysis randomized controlled trials investigating the effects in heart patients. Methods: searched PubMed, Scopus ScienceDirect...